Fig. 6

GSK872 attenuated the increased extracellular levels of potassium and glutamate in the hippocampus within 72 h after LPS injection. A The experimental protocol. One day after the chronic indwelling guide cannula was implanted in the hippocampus, mice were treated with GSK872 (2 mg/kg, i.p.) or vehicle (0.25% DMSO) 1 h before 4 mg/kg LPS was given. Microdialysis experiments were performed 1 h before GSK872 injection. Samples were collected once every 30 min for 5 h from each mouse after 1 h stabilization, and the first three samples were defined as the basal levels (100%). B and C The time course concentrations of extracellular potassium and glutamate in the hippocampus after GSK872 plus LPS treatment (n = 6 per group). Data represent percentages (mean ± standard error of the mean (SEM)) of values. Using two-way repeated measures ANOVA analysis, Bonferroni post hoc analysis revealed that GSK872 significantly inhibited the increase in potassium levels and glutamate levels induced by LPS given systemically. At 72 h after LPS injection, additional microdialysis experiments were performed in treated mice with sample collection once every 30 min for 2 h from each mouse after 1 h stabilization. D and E Mean levels of extracellular potassium and glutamate in the hippocampus 72 h after LPS treatment (n = 6 per group). Data represent the mean ± SEM of values. One-way ANOVA; Bonferroni post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001